Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights
Read More
Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up its cash position via the sale of distribution rights in Russia for their cystic fibrosis treatment which is gathering international momentum. The deal will send exclusive distribution rights in Russia to specialty company GEN İlaç
Read More
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one. In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million
Read More
The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment Bronchitol is rapidly emerging as the preferred treatment by CF sufferers in the United States. Researched and manufactured in Australia, Bronchitol gained commercial approval from the US Food and Drug Administration (FDA) in October 2020
Read More